CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 3, 2023--

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:45 am PT (12:45 pm ET) at The Westin St. Francis in San Francisco. This presentation will include an update on unaudited fourth quarter and full year 2022 global net product revenues.

A live audio webcast of both the presentation and Q&A session will be available on the Investors section of the Company’s website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.

About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO ® (patisiran), GIVLAARI ® (givosiran), OXLUMO ® (lumasiran), AMVUTTRA ® (vutrisiran) and Leqvio ® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “ Alnylam P 5 x25 ” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.

View source version on businesswire.com:https://www.businesswire.com/news/home/20230103005565/en/

CONTACT: Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom

(Investors and Media)

617-682-4340Josh Brodsky

(Investors)

617-551-8276

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL GENETICS HEALTH

SOURCE: Alnylam Pharmaceuticals, Inc.

Copyright Business Wire 2023.

PUB: 01/03/2023 04:00 PM/DISC: 01/03/2023 04:01 PM

http://www.businesswire.com/news/home/20230103005565/en